Cited by 33Hair Growth and DisordersGlaucoma and retinal disordersOcular Surface and Contact Lens

Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement

Woodward, Julie A, Haggerty, Chris J, Stinnett, Sandra S, Williams, Zinaria Y·2010·Journal of Cosmetic Dermatology

Abstract

Summary: Objective To evaluate a bimatoprost gel for enhancing eyelash growth, adverse effects, and change in intraocular pressure (IOP). Methods Prospective, double‐masked, randomized controlled study. Fifty‐two patients without ocular disease were assigned a control or bimatoprost 0.03% gel to apply to the eyelid margin once a day. Results The adjusted mean change in eyelash length from baseline to 6 months was 0.77 mm in the bimatoprost group and −0.12 mm in the control group (P = 0.004). Adverse effects were experienced by 2 of 16 patients (12.5%) in the control group and 9 of 36 patients (25%) in the bimatoprost gel group. Mean change in IOP from baseline to 6 months was 0.685 mmHg in the control group and −2.04 mmHg in the bimatoprost group (P = 0.009). Conclusions Bimatoprost gel was effective in enhancing eyelash growth. The most common adverse effect for the bimatoprost gel was conjunctival and eyelid hyperemia, while the most severe was recurrent anterior uveitis. Mean IOP was reduced in subjects using the bimatoprost gel.

Integrity signals

Registry

Crossref · 10.1111/j.1473-2165.2010.00487.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Bimatoprost 0.03% has enhanced eyelash prominence in clinical trials enrolling mostly Caucasian subjects.

    “Bimatoprost 0.03 % has enhanced eyelash prominence in clinical trials enrolling mostly Caucasian subjects.”
  • The types of adverse events reported in the current trials were consistent with those of prior studies investigating mostly Caucasian populations with hypotrichosis of the eyelashes.

    “The types of AEs reported in the current trials were consistent with those of prior studies investigating mostly Caucasian populations with hypotrichosis of the eyelashes [15, 17].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Woodward, J. A., Haggerty, C. J., Stinnett, S. S., & Williams, Z. Y.
Affiliations
Duke University (US)
Venue
Journal of Cosmetic Dermatology
Publisher
Wiley
Published
2010-06
Volume
9
Issue
2
Pages
96-102
ISSN
  • 1473-2130 (ISSN-L)
  • 1473-2165
OpenAlex
W2170423164
Cited by
33
References
1
Citations by year
2025: 1 · 2024: 4 · 2023: 1 · 2022: 2 · 2021: 4 · 2017: 3 · 2016: 1 · 2015: 1 · 2014: 7 · 2013: 4 · 2012: 3
FWCI
3.92
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Cosmetic Dermatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Research to Prevent Blindness
  • Allergan
Topics
  • Health Sciences › Medicine › Urology › Hair Growth and Disorders
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ocular Surface and Contact Lens
Keywords
bimatoprost, eyelash growth, intraocular pressure, adverse effects, conjunctival hyperemia, anterior uveitis, prostamide
MeSH terms
Bimatoprost, Adult, Aged, Amides, Cloprostenol, Double-Blind Method, Eyelashes, Female, Humans, Male, Middle Aged, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review